Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Exact Sciences Corp.

Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences to Participate in June Investor Conference
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Earns 2025 Great Place To Work® Certification™
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences to Participate in May Investor Conference
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Announces First-Quarter 2025 Results
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Schedules First Quarter 2025 Earnings Call
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
PreventionGenetics Assumes the Management of Sponsored Genetic Testing Program for Three Rare Genetic Diseases: Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1 & Hereditary ATTR Amyloidosis
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences to Participate in March Investor Conferences
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Announces Fourth Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Schedules Fourth Quarter 2024 Earnings Call
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Announces Preliminary Fourth Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences to Participate in J.P. Morgan Healthcare Conference
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences and Lil Jon Partner on “Get Low #2” Campaign to Encourage Colon Cancer Screening
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in December Investor Conferences
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Partners with Actor and TV Personality Carlos Ponce to Increase Awareness of Colon Cancer Screening Among Hispanic Community
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Announces Third-Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences to Participate in November Investor Conference
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Exact Sciences Schedules Third Quarter 2024 Earnings Call
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.